{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T03:35:45Z","timestamp":1773977745546,"version":"3.50.1"},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2169\/internalmedicine.56.7380","type":"journal-article","created":{"date-parts":[[2016,12,31]],"date-time":"2016-12-31T17:14:05Z","timestamp":1483204445000},"page":"79-83","source":"Crossref","is-referenced-by-count":7,"title":["Interstitial Lung Disease Induced by Pazopanib Treatment"],"prefix":"10.2169","volume":"56","author":[{"given":"Shotaro","family":"Ide","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan"},{"name":"Department of Infectious Diseases, Unit of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriho","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Kakugawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoji","family":"Futsuki","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Saiseikai Nagasaki Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Izumikawa","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Unit of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Ishimatsu","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Unit of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Yanagihara","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Schutz FA, Choueiri TK, Sternberg CN. Pazopanib: clinical development of a potent anti-angiogenic drug. Crit Rev Oncol Hematol 77: 163-171, 2011.","DOI":"10.1016\/j.critrevonc.2010.02.012"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28: 1061-1068, 2010.","DOI":"10.1200\/JCO.2009.23.9764"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379: 1879-1886, 2012.","DOI":"10.1016\/S0140-6736(12)60651-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Tan Q, Wang W, Long Y, Chen G. Therapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: a meta-analysis. Exp Ther Med 9: 2275-2280, 2015.","DOI":"10.3892\/etm.2015.2427"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Verschoor AJ, Gelderblom H. Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series. Clin Sarcoma Res 4: 14, 2014.","DOI":"10.1186\/2045-3329-4-14"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Leuzzi G, Alessandrini G, Ferraresi V, Ferretti G, Forcella D, Facciolo F. Bilateral spontaneous pneumothorax and massive pneumomediastinum under pazopanib therapy. Thorac Cancer 6: 110-111, 2015.","DOI":"10.1111\/1759-7714.12165"},{"key":"7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.lungcan.2013.11.016","volume":"83","author":"L Shi","year":"2014","unstructured":"7. Shi L, Tang J, Tong L, Liu Z. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials. Lung Cancer 83: 231-239, 2014.","journal-title":"Lung Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0169-5002","issn-type":"print"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Qi WX, Sun YJ, Shen Z, Yao Y. Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials. J Chemother 27: 40-51, 2015.","DOI":"10.1179\/1973947814Y.0000000189"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Myung HJ, Jeong SH, Kim JW, et al. Sorafenib-induced interstitial pneumonitis in a patient with hepatocellular carcinoma: a case report. Gut Liver 4: 543-546, 2010.","DOI":"10.5009\/gnl.2010.4.4.543"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Ide S, Soda H, Hakariya T, et al. Interstitial pneumonia probably associated with sorafenib treatment: an alert of an adverse event. Lung Cancer 67: 248-250, 2010.","DOI":"10.1016\/j.lungcan.2009.10.007"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Takeda H, Nishikawa H, Iguchi E, et al. Sorafenib-induced acute interstitial pneumonia in patients with advanced hepatocellular carcinoma: report of three cases. Clin J Gastroenterol 5: 407-412, 2012.","DOI":"10.1007\/s12328-012-0339-9"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Horiuchi-Yamamoto Y, Gemma A, Taniguchi H, et al. Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan. Int J Clin Oncol 18: 743-749, 2013.","DOI":"10.1007\/s10147-012-0438-0"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yamaguchi T, Seki T, Miyasaka C, et al. Interstitial pneumonia induced by sorafenib in a patient with hepatocellular carcinoma: an autopsy case report. Oncol Lett 9: 1633-1636, 2015.","DOI":"10.3892\/ol.2015.2934"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Abramson RG, Abramson VG, Chan E, et al. Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. AJR Am J Roentgenol 200: 475-483, 2013.","DOI":"10.2214\/AJR.12.9049"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Miettinen PJ, Warburton D, Bu D, et al. Impaired lung branching morphogenesis in the absence of functional EGF receptor. Dev Biol 186: 224-236, 1997.","DOI":"10.1006\/dbio.1997.8593"},{"key":"16","unstructured":"16. Suzuki H, Aoshiba K, Yokohori N, Nagai A. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res 63: 5054-5059, 1997."},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Takano T, Ohe Y, Kusumoto M, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 45: 93-104, 2004.","DOI":"10.1016\/j.lungcan.2004.01.010"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 24: 2549-2556, 2006.","DOI":"10.1200\/JCO.2005.04.9866"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kudoh S, Kato H, Nishiwaki Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 177: 1348-1357, 2008.","DOI":"10.1164\/rccm.200710-1501OC"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kubo K, Azuma A, Kanazawa M, et al. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig 51: 260-277, 2013.","DOI":"10.1016\/j.resinv.2013.09.001"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/1\/56_56.7380\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T03:06:18Z","timestamp":1498359978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/1\/56_56.7380\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.56.7380","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}